One year of procarbazine lomustine and vincristine is poorly tolerated in low grade glioma: a real world experience in a national neuro-oncology centre

Table 1 Patient Baseline Characteristics

	Age < 40 N = 20		Age ≥ 40 N = 21		Total N = 41 (%)		p-value
	N	%	N	%	N	%	p-value
Sex:							0.412^a
Male	13	65	11	52	24	58
Female	7	35	10	48	17	41
Recurrent/First Diagnosis:							0.427^a
First Diagnosis	12	60	10	48	22	54
Recurrent	8	40	11	52	19	46
Surgery:							1.00^b
Resection	18	90	20	95	38	93
Biopsy	2	10	1	5	3	7
Histology:							0.002^a
Oligodendroglioma	9	45	19	90	28	68
Astrocytoma	11	55	2	9	13	32
IDH:							1.00^b
Mutated	19	95	19	90	38	93
Wildtype	0	0	0	0	0	0
Unknown	1	5	2	9	3	7
1p19q Co-deletion:							0.001^a
Present	7	35	18	86	25	61
Absent	10	50	2	9	12	29
Unknown	3	15	1	5	4	10
MGMT
Methylated	8	40	6	29	14	34
Unmethylated	1	5	0	0	1	2.4
Unknown	11	55	15	71	26	63
ATRX
Mutated	5	25	1	5	6	15
Wildtype	3	15	8	38	11	27
Unknown	12	60	12	57	24	58

Each value is represented by number of patients (N) and percentage of patients (%)
^aChi-square test for independence
^bFisher’s exact test

ISSN: 1471-2407